Ajax Therapeutics key facts
- Developer of targeted therapy drugs designed for the treatment of hematologic cancers.
- Ajax Therapeutics’s last known valuation is $192.5M.
- It has raised $143.0M across 3 recorded rounds; the latest was Later Stage VC (Series C) ($95.0M) in May 2024.
- Notable investors include RA Capital Management, Point72 Ventures, Goldman Sachs Asset Management, Vivo Capital, EcoR1 Capital — 11 tracked in total.
- Ajax Therapeutics has filed 3 Form Ds with the SEC since 2019, most recently May 2024 ($95.0M sold to 21 investors).
- Status: Privately Held (backing).
Who backs Ajax Therapeutics
11+- ·The complete investor list: 11 names
- ·Watch Ajax Therapeutics: the Monday email on marks, rounds and moves
Ajax Therapeutics funding rounds
3 roundsAjax Therapeutics valuation
Ajax Therapeutics's last known valuation is $193 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
How much has Ajax Therapeutics raised?
Ajax Therapeutics has raised $143 million across 3 recorded rounds since 2019. The largest was a $95 million Series C in May 2024.
Ajax Therapeutics has filed 3 Form Ds with the SEC since 2019, most recently in May 2024 ($95 million sold to 21 investors).
Ajax Therapeutics investors
11 investors are on record for Ajax Therapeutics, including RA Capital Management, Point72 Ventures, Goldman Sachs Asset Management and Vivo Capital. The Series C in May 2024 drew 8 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Plexium ($200 million), Kinaset Therapeutics ($186 million) and Cambrian Bio ($180 million).
About Ajax Therapeutics
Developer of targeted therapy drugs designed for the treatment of hematologic cancers. The company leverages advances in molecular genetics and biology to develop new classes of therapies that are highly selective for specific drug targets, while aiming to minimize interactions with related proteins, enabling healthcare providers to access effective and precise treatment options for patients with blood cancers.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2019
- Employees
- 9
- Website
- ajaxtherapeutics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Ajax Therapeutics’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.